Meet Proteona at the AVCO Annual Conference 2019 in Vienna, Austria
Innovative AI-driven genomic and proteomic analysis platform for improving cell therapy and immuno-oncology
Dr Andreas Schmidt, the CEO of Proteona Pte. Ltd., will be presenting at the AVCO Annual Conference 2019, taking place on the 3rd of October in Vienna, Austria.
Dr Schmidt will speak in the panel “Investing in Healthcare Opportunities in Europe” at 17:10pm. The annual conference is Austria’s leading event for investors and entrepreneurs.
For media queries, please contact:
Dr Andreas Schmidt
Proteona is a precision medicine company in Singapore, Germany, and the US that is pioneering the use of single cell multi-omics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona enables pharmaceutical companies, biotech partners, and clinicians to integrate single cell level precision into their clinical projects. Proteona continues to develop comprehensive, disease-specific single cell databases combining gene expression, protein expression, and mutation information derived from each individual cells as well as drug response data for each sample. Proteona has been selected as a “One to Watch” by Nature Research Spinoff Award and a Winner of Falling Walls Ventures Breakthrough of the Year 2020. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR).